5 years of cardiovascular benefits of GLP-1 receptor agonists: evidence from recent cardiovascular outcomes trials

Thursday, 30 September 2021, 10:00 - 11:30, Saint Petersburg Hall

Chair: J. Buse, US

D.J. Drucker, CA: The evolution of GLP-1 receptor agonist

S.P. Marso, US: Cardiovascular benefits of GLP-1 receptor agonists: evidence from recent outcome trials

O. Mosenzon, IL: Renal benefits of GLP-1 receptor agonists: evidence from recent outcome trials

N. Marx, DE: Mechanistic insights in the cardiorenal benefits of GLP-1 receptor agonists

I. Lingvay, US: Impact of guidelines on management of T2D and future directions of GLP-1 receptor agonists

Panel Discussion